

# LucÃ-ia Saraiva

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6956054/publications.pdf>

Version: 2024-02-01

106  
papers

1,778  
citations

293460

24  
h-index

425179

34  
g-index

108  
all docs

108  
docs citations

108  
times ranked

2613  
citing authors

#	ARTICLE	IF	CITATIONS
1	Noncanonical roles of p53 in cancer stemness and their implications in sarcomas. <i>Cancer Letters</i> , 2022, 525, 131-145.	3.2	10
2	Mutant p53 reactivator SLMP53-2 hinders ultraviolet B radiation-induced skin carcinogenesis. <i>Pharmacological Research</i> , 2022, 175, 106026.	3.1	3
3	Enhanced Anticancer Activity of Hymenocardia acida Stem Bark Extract Loaded into PLGA Nanoparticles. <i>Pharmaceuticals</i> , 2022, 15, 535.	1.7	5
4	Folic acid-mesoporous silicon nanoparticles enhance the anticancer activity of the p73-activating small molecule LEM2. <i>International Journal of Pharmaceutics</i> , 2022, 624, 121959.	2.6	0
5	Potency and Selectivity Optimization of Tryptophanolâ€Derived Oxazoloisindolinones: Novel p53 Activators in Human Colorectal Cancer. <i>ChemMedChem</i> , 2021, 16, 250-258.	1.6	6
6	Development of lipid nanoparticles containing the xanthone LEM2 for topical treatment of melanoma. <i>Journal of Drug Delivery Science and Technology</i> , 2021, 61, 102226.	1.4	15
7	Mechanism of Antifungal Activity by 5-Aminoimidazole-4-Carbohydrazonamide Derivatives against <i>Candida albicans</i> and <i>Candida krusei</i> . <i>Antibiotics</i> , 2021, 10, 183.	1.5	15
8	Semi-Synthesis of Small Molecules of Aminocarbazoles: Tumor Growth Inhibition and Potential Impact on p53. <i>Molecules</i> , 2021, 26, 1637.	1.7	4
9	A selective p53 activator and anticancer agent to improve colorectal cancer therapy. <i>Cell Reports</i> , 2021, 35, 108982.	2.9	20
10	Targeting p53 for Melanoma Treatment: Counteracting Tumour Proliferation, Dissemination and Therapeutic Resistance. <i>Cancers</i> , 2021, 13, 1648.	1.7	11
11	Preliminary Biological Activity Screening of <i>Plectranthus</i> spp. Extracts for the Search of Anticancer Lead Molecules. <i>Pharmaceuticals</i> , 2021, 14, 402.	1.7	11
12	Chalcones as Promising Antitumor Agents by Targeting the p53 Pathway: An Overview and New Insights in Drug-Likeness. <i>Molecules</i> , 2021, 26, 3737.	1.7	17
13	BBIT20 inhibits homologous DNA repair with disruption of the BRCA1â€BARD1 interaction in breast and ovarian cancer. <i>British Journal of Pharmacology</i> , 2021, 178, 3627-3647.	2.7	13
14	Structural and Drug Targeting Insights on Mutant p53. <i>Cancers</i> , 2021, 13, 3344.	1.7	38
15	Exploiting DNA Damage Repair in Precision Cancer Therapy: BRCA1 as a Prime Therapeutic Target. <i>Cancers</i> , 2021, 13, 3438.	1.7	11
16	A Diarylpentanoid with Potential Activation of the p53 Pathway: Combination of <i>in silico</i> Screening Studies, Synthesis, and Biological Activity Evaluation. <i>ChemMedChem</i> , 2021, 16, 2969-2981.	1.6	7
17	Cytotoxicity of Frutalin on Distinct Cancer Cells Is Independent of Its Glycosylation. <i>Molecules</i> , 2021, 26, 4712.	1.7	1
18	Self-Assembly Nanoparticles of Natural Bioactive Abietane Diterpenes. <i>International Journal of Molecular Sciences</i> , 2021, 22, 10210.	1.8	5

#	ARTICLE	IF	CITATIONS
19	Abstract P030: Chemoprevention by the mutant p53 reactivator SLMP53-2 on ultraviolet radiation-induced skin cancer. , 2021, , .		0
20	SLMP53-1 interacts with wild-type and mutant p53 DNA-binding domain and reactivates multiple hotspot mutations. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 2020, 1864, 129440.	1.1	13
21	BRCA1/P53: Two strengths in cancer chemoprevention. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2020, 1873, 188339.	3.3	17
22	p73: From the p53 shadow to a major pharmacological target in anticancer therapy. <i>Pharmacological Research</i> , 2020, 162, 105245.	3.1	15
23	P53 in skin cancer: From a master player to a privileged target for prevention and therapy. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2020, 1874, 188438.	3.3	29
24	Boronic Acids and Their Derivatives in Medicinal Chemistry: Synthesis and Biological Applications. <i>Molecules</i> , 2020, 25, 4323.	1.7	75
25	Activity to Breast Cancer Cell Lines of Different Malignancy and Predicted Interaction with Protein Kinase C Isoforms of Royleanones. <i>International Journal of Molecular Sciences</i> , 2020, 21, 3671.	1.8	7
26	Diarylpentanoids with antitumor activity: A critical review of structure-activity relationship studies. <i>European Journal of Medicinal Chemistry</i> , 2020, 192, 112177.	2.6	26
27	SLMP53-1 Inhibits Tumor Cell Growth through Regulation of Glucose Metabolism and Angiogenesis in a P53-Dependent Manner. <i>International Journal of Molecular Sciences</i> , 2020, 21, 596.	1.8	17
28	Norhierridin B, a New Hierridin B-Based Hydroquinone with Improved Antiproliferative Activity. <i>Molecules</i> , 2020, 25, 1578.	1.7	5
29	Small Molecules Targeting Mutant P53: A Promising Approach for Cancer Treatment. <i>Current Medicinal Chemistry</i> , 2020, 26, 7323-7336.	1.2	13
30	SLMP53-2 Restores Wild-Type-Like Function to Mutant p53 through Hsp70: Promising Activity in Hepatocellular Carcinoma. <i>Cancers</i> , 2019, 11, 1151.	1.7	21
31	Yeast As a Chassis for Developing Functional Assays to Study Human P53. <i>Journal of Visualized Experiments</i> , 2019, , .	0.2	9
32	Naphthoylhydrazones: coordination to metal ions and biological screening. <i>New Journal of Chemistry</i> , 2019, 43, 17801-17818.	1.4	13
33	Parvifloron D from <i>Plectranthus strigosus</i> : Cytotoxicity Screening of <i>Plectranthus</i> spp. Extracts. <i>Biomolecules</i> , 2019, 9, 616.	1.8	8
34	Strategies to Discover p53 Activators and a p73 Activator for Neuroblastoma. <i>Proceedings (mdpi)</i> , 2019, 22, .	0.2	0
35	Targeting leucine-rich repeat kinase 2 (LRRK2) for the treatment of Parkinson's disease. <i>Future Medicinal Chemistry</i> , 2019, 11, 1953-1977.	1.1	16
36	New inhibitor of the TAp73 interaction with MDM2 and mutant p53 with promising antitumor activity against neuroblastoma. <i>Cancer Letters</i> , 2019, 446, 90-102.	3.2	36

#	ARTICLE	IF	CITATIONS
37	A simple linearization method unveils hidden enzymatic assay interferences. <i>Biophysical Chemistry</i> , 2019, 252, 106193.	1.5	6
38	Synthesis, Biological Evaluation, and In Silico Studies of Novel Aminated Xanthenes as Potential p53-Activating Agents. <i>Molecules</i> , 2019, 24, 1975.	1.7	24
39	Comparison Study of Different Extracts of <i>Plectranthus madagascariensis</i> , <i>P. neochilus</i> and the Rare <i>P. porcatus</i> (Lamiaceae): Chemical Characterization, Antioxidant, Antimicrobial and Cytotoxic Activities. <i>Biomolecules</i> , 2019, 9, 179.	1.8	15
40	Cytotoxic Activity of Royleanone Diterpenes from <i>Plectranthus madagascariensis</i> Benth. <i>ACS Omega</i> , 2019, 4, 8094-8103.	1.6	24
41	New Alkoxy Flavone Derivatives Targeting Caspases: Synthesis and Antitumor Activity Evaluation. <i>Molecules</i> , 2019, 24, 129.	1.7	15
42	Design and synthesis of new inhibitors of p53-MDM2 interaction with a chalcone scaffold. <i>Arabian Journal of Chemistry</i> , 2019, 12, 4150-4161.	2.3	21
43	Discovery of a small-molecule protein kinase C $\delta$ -selective activator with promising application in colon cancer therapy. <i>Cell Death and Disease</i> , 2018, 9, 23.	2.7	25
44	p53 and glucose metabolism: an orchestra to be directed in cancer therapy. <i>Pharmacological Research</i> , 2018, 131, 75-86.	3.1	83
45	Biological Effects of Saponin Fractions from <i>Astragalus verrucosus</i> in Tumor and Non-tumor Human cells. <i>Natural Product Communications</i> , 2018, 13, 1934578X1801300.	0.2	4
46	The Crystal Structure of the R280K Mutant of Human p53 Explains the Loss of DNA Binding. <i>International Journal of Molecular Sciences</i> , 2018, 19, 1184.	1.8	23
47	Improving anticancer activity towards colon cancer cells with a new p53-activating agent. <i>British Journal of Pharmacology</i> , 2018, 175, 3947-3962.	2.7	21
48	Targeting the MDM2-p53 protein-protein interaction with prenylchalcones: Synthesis of a small library and evaluation of potential antitumor activity. <i>European Journal of Medicinal Chemistry</i> , 2018, 156, 711-721.	2.6	22
49	The crystal structure of the R280K mutant of human p53 explains the loss of DNA binding. <i>Acta Crystallographica Section A: Foundations and Advances</i> , 2018, 74, e192-e192.	0.0	0
50	DIMP53-1: a novel small-molecule dual inhibitor of p53-MDM2/X interactions with multifunctional p53-dependent anticancer properties. <i>Molecular Oncology</i> , 2017, 11, 612-627.	2.1	33
51	Natural Products as Lead Protein Kinase C Modulators for Cancer Therapy. <i>Studies in Natural Products Chemistry</i> , 2016, , 45-79.	0.8	12
52	Medicinal Chemistry Strategies to Disrupt the p53-MDM2/MDMX Interaction. <i>Medicinal Research Reviews</i> , 2016, 36, 789-844.	5.0	71
53	Hydrogen peroxide-induced secondary necrosis in conidia of <i>Aspergillus fumigatus</i> . <i>Canadian Journal of Microbiology</i> , 2016, 62, 95-101.	0.8	4
54	p53 family interactions and yeast: together in anticancer therapy. <i>Drug Discovery Today</i> , 2016, 21, 616-624.	3.2	11

#	ARTICLE	IF	CITATIONS
55	Reactivation of wild-type and mutant p53 by tryptophan-derived oxazoloisoindolinone SLMP53-1, a novel anticancer small-molecule. <i>Oncotarget</i> , 2016, 7, 4326-4343.	0.8	37
56	A yeast model of the Parkinson's disease-associated protein Parkin. <i>Experimental Cell Research</i> , 2015, 333, 73-79.	1.2	22
57	A tryptophan-derived oxazolopiperidone lactam is cytotoxic against tumors via inhibition of p53 interaction with murine double minute proteins. <i>Pharmacological Research</i> , 2015, 95-96, 42-52.	3.1	37
58	Enhanced cytotoxicity of prenylated chalcone against tumour cells via disruption of the p53-MDM2 interaction. <i>Life Sciences</i> , 2015, 142, 60-65.	2.0	28
59	Chronological aging in conidia of pathogenic <i>Aspergillus</i> : Comparison between species. <i>Journal of Microbiological Methods</i> , 2015, 118, 57-63.	0.7	9
60	Studying p53 family proteins in yeast: Induction of autophagic cell death and modulation by interactors and small molecules. <i>Experimental Cell Research</i> , 2015, 330, 164-177.	1.2	11
61	Oxazoloisoindolinones with in vitro antitumor activity selectively activate a p53-pathway through potential inhibition of the p53-MDM2 interaction. <i>European Journal of Pharmaceutical Sciences</i> , 2015, 66, 138-147.	1.9	41
62	Potential small-molecule activators of caspase-7 identified using yeast-based caspase-3 and -7 screening assays. <i>European Journal of Pharmaceutical Sciences</i> , 2014, 54, 8-16.	1.9	9
63	Microglia P2Y6 receptors mediate nitric oxide release and astrocyte apoptosis. <i>Journal of Neuroinflammation</i> , 2014, 11, 141.	3.1	44
64	LRRK2, but not pathogenic mutants, protects against H <sub>2</sub> O <sub>2</sub> stress depending on mitochondrial function and endocytosis in a yeast model. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 2014, 1840, 2025-2031.	1.1	29
65	Using yeast to uncover the regulation of protein kinase C $\beta$ by ceramide. <i>FEMS Yeast Research</i> , 2013, 13, 700-705.	1.1	3
66	Interference of aging media on the assessment of yeast chronological life span by propidium iodide staining. <i>Folia Microbiologica</i> , 2013, 58, 81-84.	1.1	7
67	Î±-Mangostin and Gambogic Acid as Potential Inhibitors of the p53-MDM2 Interaction Revealed by a Yeast Approach. <i>Journal of Natural Products</i> , 2013, 76, 774-778.	1.5	36
68	Discovery of a new small-molecule inhibitor of p53-MDM2 interaction using a yeast-based approach. <i>Biochemical Pharmacology</i> , 2013, 85, 1234-1245.	2.0	55
69	Novel simplified yeast-based assays of regulators of p53-MDMX interaction and p53 transcriptional activity. <i>FEBS Journal</i> , 2013, 280, 6498-6507.	2.2	16
70	SNaPaer: A Practical Single Nucleotide Polymorphism Multiplex Assay for Genotyping of <i>Pseudomonas aeruginosa</i> . <i>PLoS ONE</i> , 2013, 8, e66083.	1.1	11
71	Contribution of Yeast and Plant Research for Improving Human Health. <i>Journal of Biomedicine and Biotechnology</i> , 2012, 2012, 1-2.	3.0	0
72	Contribution of Yeast Models to Neurodegeneration Research. <i>Journal of Biomedicine and Biotechnology</i> , 2012, 2012, 1-12.	3.0	39

#	ARTICLE	IF	CITATIONS
73	New Therapeutic Strategies for Cancer and Neurodegeneration Emerging from Yeast Cell-based Systems. <i>Current Pharmaceutical Design</i> , 2012, 18, 4223-4235.	0.9	24
74	Production and purification of the VP1 capsid protein of a novel canine norovirus using the <i>Saccharomyces cerevisiae</i> expression system. <i>Journal of Microbiological Methods</i> , 2012, 91, 358-360.	0.7	2
75	953 Discovery of a New Inhibitor of P53/MDM2 Interaction Using a Yeast Target-based Screening Strategy. <i>European Journal of Cancer</i> , 2012, 48, S229.	1.3	0
76	New insights into cancer-related proteins provided by the yeast model. <i>FEBS Journal</i> , 2012, 279, 697-712.	2.2	42
77	Endocytosis inhibition during H <sub>2</sub> O <sub>2</sub> -induced apoptosis in yeast. <i>FEMS Yeast Research</i> , 2012, 12, 755-760.	1.1	12
78	Yeast as a Powerful Model System for the Study of Apoptosis Regulation by Protein Kinase C Isoforms. <i>Current Pharmaceutical Design</i> , 2012, 18, 2492-2500.	0.9	7
79	The Importance of Humanized Yeast to Better Understand the Role of Bcl-2 Family in Apoptosis: Finding of Novel Therapeutic Opportunities. <i>Current Pharmaceutical Design</i> , 2011, 17, 246-255.	0.9	22
80	Modulation of Bax mitochondrial insertion and induced cell death in yeast by mammalian protein kinase C $\delta$ . <i>Experimental Cell Research</i> , 2011, 317, 781-790.	1.2	23
81	Distinct regulation of p53-mediated apoptosis by protein kinase C $\delta$ , $\epsilon$ , $\mu$ and $\eta$ : Evidence in yeast for transcription-dependent and -independent p53 apoptotic mechanisms. <i>Experimental Cell Research</i> , 2011, 317, 1147-1158.	1.2	20
82	Aspartic vinyl sulfones: Inhibitors of a caspase-3-dependent pathway. <i>European Journal of Medicinal Chemistry</i> , 2011, 46, 2141-2146.	2.6	25
83	Selective activation of protein kinase C $\delta$ and $\epsilon$ by 6,11,12,14-tetrahydroxy-abieta-5,8,11,13-tetraene-7-one (coleon U). <i>Biochemical Pharmacology</i> , 2009, 78, 449-459.	2.0	15
84	Differential regulation of p53 function by protein kinase C isoforms revealed by a yeast cell system. <i>FEBS Letters</i> , 2009, 583, 3582-3588.	1.3	17
85	Specific modulation of apoptosis and Bcl-xL phosphorylation in yeast by distinct mammalian protein kinase C isoforms. <i>Journal of Cell Science</i> , 2006, 119, 3171-3181.	1.2	41
86	Characterization of phorbol esters activity on individual mammalian protein kinase C isoforms, using the yeast phenotypic assay. <i>European Journal of Pharmacology</i> , 2004, 491, 101-110.	1.7	27
87	Inhibition of protein kinase C by synthetic xanthone derivatives. <i>Bioorganic and Medicinal Chemistry</i> , 2003, 11, 1215-1225.	1.4	34
88	Isoform-selectivity of PKC Inhibitors Acting at the Regulatory and Catalytic Domain of Mammalian PKC $\delta$ , $\epsilon$ , $\zeta$ , $\eta$ and $\theta$ . <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 2003, 18, 475-483.	2.5	21
89	Inhibition of $\delta$ , $\epsilon$ , $\zeta$ , $\eta$ and $\theta$ Protein Kinase C Isoforms by Xanthonolignoids. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 2003, 18, 357-370.	2.5	18
90	Differential Activation of Protein Kinase C Isoforms by Euxanthone, Revealed by an In Vivo Yeast Phenotypic Assay. <i>Planta Medica</i> , 2002, 68, 1039-1041.	0.7	9

#	ARTICLE	IF	CITATIONS
91	Synthesis and in vivo modulatory activity of protein kinase C of xanthone derivatives. <i>Bioorganic and Medicinal Chemistry</i> , 2002, 10, 3219-3227.	1.4	37
92	Differential Activation by Daphnetoxin and Mezerein of PKC-Isotypes $\hat{\iota}\pm$ , $\hat{\iota}2$ , $\hat{\iota}$ and $\hat{\iota}\eta$ . <i>Planta Medica</i> , 2001, 67, 787-790.	0.7	22
93	Promising caspase modulators with flavonoid scaffold. , 0, , .		0
94	Enantiopure oxazoloisoindolinones: Promising small molecules for p53-based therapy with potential anticancer properties. , 0, , .		0
95	Design and molecular docking studies of new potential PKC- $\hat{\iota}$ activators based on royleanone scaffold. , 0, , .		0
96	Improving colon cancer therapy with a new promising small-molecule activator of the p53-pathway through disruption of p53-MDM2/MDMX interactions. , 0, , .		0
97	Cytotoxic activity of coleon diterpenoids from <i>Plectranthus mutabilis</i> codd. , 0, , .		0
98	Tryptophan-derived oxazoloisoindolinones: Novel small molecule p53 activators with promising antitumor activity. , 0, , .		0
99	Targeting neuroblastoma with a new inhibitor of the TAp73 interaction with MDM2 and mutant p53. , 0, , .		0
100	Optimizing the oxazoloisoindolinone family: Identification and biological evaluation of a potent and selective indole-based p53 activator in human colorectal cancer. , 0, , .		0
101	Chemical Composition and Biological Activity of Diterpenoids from <i>Plectranthus mutabilis</i> . , 0, , .		0
102	SLMP53-1 inhibits tumor cell growth through regulation of glucose metabolism and angiogenesis in a P53-dependent manner. , 0, , .		0
103	Norhierridin B, a new hierridin B-based hydroquinone with improved antiproliferative activity. , 0, , .		0
104	BP-C4: A new diarylpentanoid with potential activation of the p53 pathway. , 0, , .		0
105	Chemoprevention of ultraviolet B radiation-induced skin cancer with the mutant p53 reactivator SLMP53-2. , 0, , .		0
106	Inhibition of P-glycoprotein activity to overcome multidrug resistance in cancer with new diterpene royleanones from <i>Plectranthus</i> spp.. , 0, , .		0